Aries Wealth Management boosted its position in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 0.9% in the 3rd quarter, Holdings Channel.com reports. The fund owned 30,985 shares of the company’s stock after purchasing an additional 273 shares during the period. Johnson & Johnson makes up 2.4% of Aries Wealth Management’s holdings, making the stock its 7th largest holding. Aries Wealth Management’s holdings in Johnson & Johnson were worth $5,390,000 at the end of the most recent reporting period.
Several other large investors have also recently bought and sold shares of JNJ. Hardman Johnston Global Advisors LLC increased its stake in shares of Johnson & Johnson by 0.9% during the third quarter. Hardman Johnston Global Advisors LLC now owns 156,567 shares of the company’s stock valued at $25,577,000 after buying an additional 1,335 shares during the period. Rice Partnership LLC increased its position in Johnson & Johnson by 12.3% during the 3rd quarter. Rice Partnership LLC now owns 53,655 shares of the company’s stock valued at $8,765,000 after purchasing an additional 5,868 shares during the period. Aptus Capital Advisors LLC raised its holdings in Johnson & Johnson by 7.2% in the 3rd quarter. Aptus Capital Advisors LLC now owns 77,500 shares of the company’s stock worth $12,661,000 after purchasing an additional 5,177 shares in the last quarter. Fagan Associates Inc. boosted its stake in shares of Johnson & Johnson by 0.3% during the 3rd quarter. Fagan Associates Inc. now owns 46,282 shares of the company’s stock valued at $7,561,000 after purchasing an additional 145 shares in the last quarter. Finally, Summit X LLC raised its stake in Johnson & Johnson by 7.8% in the third quarter. Summit X LLC now owns 3,486 shares of the company’s stock worth $567,000 after buying an additional 252 shares in the last quarter. 67.94% of the stock is owned by institutional investors.
Insider Activity at Johnson & Johnson
In related news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares of the company’s stock, valued at approximately $6,431,835.20. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In related news, CFO Joseph J. Wolk sold 14,781 shares of the stock in a transaction that occurred on Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the completion of the transaction, the chief financial officer now directly owns 35,812 shares of the company’s stock, valued at $6,431,835.20. The sale was disclosed in a filing with the SEC, which is available through this link. Also, EVP Jennifer L. Taubert sold 76,923 shares of the company’s stock in a transaction on Tuesday, November 22nd. The shares were sold at an average price of $176.78, for a total transaction of $13,598,447.94. Following the sale, the executive vice president now directly owns 126,456 shares in the company, valued at approximately $22,354,891.68. The disclosure for this sale can be found here. In the last quarter, insiders have sold 233,611 shares of company stock worth $40,960,735. 0.35% of the stock is owned by corporate insiders.
Wall Street Analyst Weigh In
Johnson & Johnson Stock Performance
Johnson & Johnson stock opened at $168.31 on Wednesday. The business has a 50-day simple moving average of $175.98 and a two-hundred day simple moving average of $171.06. Johnson & Johnson has a 52-week low of $155.72 and a 52-week high of $186.69. The company has a quick ratio of 1.18, a current ratio of 1.43 and a debt-to-equity ratio of 0.37. The company has a market cap of $440.04 billion, a P/E ratio of 23.44, a P/E/G ratio of 3.21 and a beta of 0.56.
Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings results on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, topping the consensus estimate of $2.23 by $0.12. The business had revenue of $23.71 billion for the quarter, compared to analysts’ expectations of $23.90 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. The company’s revenue was down 4.4% compared to the same quarter last year. During the same quarter last year, the company posted $2.13 EPS. Analysts predict that Johnson & Johnson will post 10.04 EPS for the current year.
Johnson & Johnson Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 7th. Shareholders of record on Tuesday, February 21st will be given a $1.13 dividend. The ex-dividend date of this dividend is Friday, February 17th. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.69%. Johnson & Johnson’s payout ratio is currently 62.95%.
About Johnson & Johnson
Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.
- Get a free copy of the StockNews.com research report on Johnson & Johnson (JNJ)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- Is It Time To Get Aggressive With Defense Stocks?
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.